rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032

      Cut costs and accelerate safety assessments with human-relevant in vitro models, AI, organ-on-chip and high-throughput screening amid regulatory and ethical shifts.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "In Vitro Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market was valued at US$14 billion in 2025 and is projected to reach US$27.4 billion by 2032, expanding at a compound annual growth rate

      Nov 10Yahoo FinanceBIOTMO
      Why Is Bio Rad Laboratories (BIO) Drawing Elliott’s Attention Now?

      Elliott Investment Management has taken an activist position in Bio-Rad Laboratories (NYSE:BIO), pushing for changes at the diagnostics group. The investor is calling out what it views as hidden value at Bio-Rad, including the company’s stake in Sartorius. Elliott is also urging a review of operations and capital allocation, which could lead to restructuring or asset monetization moves. The new activist pressure from Elliott on Bio-Rad’s operations and Sartorius stake is important, but it...

      Nov 10Yahoo FinanceBIO
      How Investors Are Reacting To Bio Rad (BIO) International Revenue Surprise

      Bio-Rad Laboratories reported third quarter 2026 sales of US$656.4 million and net income of US$458.6 million, compared with a loss a year earlier, alongside a US$49.8 million impairment of purchased intangibles. The swing from loss to profit, supported by stronger international revenue surprises in Asia and EMEA, highlights how overseas demand is influencing Bio-Rad Laboratories' current earnings mix. The focus now is on how this sharp earnings turnaround at Bio-Rad Laboratories could...

      Nov 10Yahoo FinanceBIO
      Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention

      Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

      Nov 9Yahoo FinanceBIO
      Is Bio-Rad Laboratories, Inc. (BIO) an Activist Investor Target With Significant Hidden Value
      Nov 7Yahoo FinanceBIO
      Bio-Rad Laboratories Inc (BIO) (Q3 2026) Earnings Call Highlights: Return to Currency-Neutral ...
      Nov 5Yahoo FinanceBIO
      Bio-Rad Laboratories Q3 2026 Earnings Call Transcript
      Nov 4BenzingaBIO
      Bio-Rad: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceBIO
      Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates
      Nov 4Yahoo FinanceBIO
      Bio-Rad earnings on deck: Transformation test amid activist pressure
      Nov 4Investing.comBIO
      Bio-Rad earnings up next: Can diagnostics firm sustain momentum?
      Nov 4Investing.comBIO
      Bio Rad Laboratories (BIO) Stock Looks Fully Valued After 49% Five Year Fall
      Oct 31Yahoo FinanceBIO
      Bio Rad Laboratories (BIO) Stock Dropped, What Is Behind The Fresh Attention?

      Bio-Rad Laboratories (BIO) drew fresh attention after CFO Roop K. Lakkaraju was slated for a fireside chat at the UBS Global Healthcare Conference, a forum investors often watch for management commentary. Recent trading tells a mixed story for Bio-Rad Laboratories. The share price is US$372.18 after a 1-day share price return that declined 3.18%. However, the 90-day share price return of 14.35% and year-to-date share price return of 21.92% point to momentum that has been building over the...

      Oct 31Yahoo FinanceBIO
      South & Central America Point of Care Diagnostics Market Size, Share, Trends and Forecast (2026-2031) Featuring Profiles of Siemens, Abbott Labs, Roche, bioMerieux, Bio-Rad Labs and More

      Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "South & Central America Point of Care Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis" has been added to ResearchAndMarkets.com's offering. The South & Central America point of care (POC) diagnostics market is projected to reach US$ 6,924.0 million by 2031, rising from US$ 3,508.9 million in 2024. According to the report, the market is expected to record a compound annual growth rate (CAGR) of 1

      Oct 29Yahoo FinanceBIO
      Reaction Monitoring - Global Strategic Business Report: Secure Share of the $2 Billion 2030 Market as Tariffs Reshape Danaher, Bruker, Bio-Rad, Waters, and Shimadzu Strategies

      Boost ROI with real-time analytics, advanced spectroscopy and PAT to optimize yields, cut waste, prevent batch failures and strengthen process safety.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Reaction Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering The global reaction monitoring market, valued at US$1.6 billion in 2024, is projected to reach US$2 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.1% between 2024 and 2030. M

      Oct 29Yahoo FinanceBRKRBIO
      Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says
      Oct 28Yahoo FinanceBIO
      BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount?
      Oct 27Yahoo FinanceBIO
      Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

      HERCULES, Calif., October 14, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.

      Oct 14Yahoo FinanceBIO
      Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
      Oct 1Yahoo FinanceBIO
      Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
      Oct 1Yahoo FinanceBIO
      RBC Capital reiterates Bio-Rad Labs stock rating on transformation outlook
      Sep 28Investing.comBIO
      Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth

      Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. Speaking at a Bernstein conference, Chief Financial Offic

      Sep 26Yahoo FinanceBIO
      Bio-Rad at bernstein healthcare forum: shift toward profitable growth
      Sep 24Investing.comBIO
      Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

      Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

      Sep 24Yahoo FinanceBDSXBIOTMO
      Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher
      Sep 24Investing.comBDSXBIOTMO
      Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius

      Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a

      Sep 24Yahoo FinanceBIO
      Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

      BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

      Sep 23Yahoo FinanceBIO
      Capitalize on Label-Free Array Systems Disruption: Benchmark Agilent, Cytiva, Sartorius, Bio-Rad and PerkinElmer to Secure R&D ROI and Global Market Share

      Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-free Array Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-free Array Systems was valued at US$1.8 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 5.6% from 2

      Sep 22Yahoo FinanceBIO
      Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

      HERCULES, Calif., September 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.

      Sep 16Yahoo FinanceBIO
      Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues

      Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price implies about the cash the business can generate. With the valuation lens focused on cash flows through a Discounted Cash Flow (DCF) framework, the question is how well today's market price lines up with the stream of money the company may produce for...

      Sep 15Yahoo FinanceBIO
      Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO)
      Sep 10Seeking AlphaBIO
      Bio-Rad at Wells Fargo conference: margin push takes center stage
      Sep 9Investing.comBIOWFC
      Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
      Sep 3Yahoo FinanceBIO
      Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

      HERCULES, Calif., August 31, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

      Aug 31Yahoo FinanceBIOWFC
      Bio-Rad Laboratories stock hits 52-week high at 394.22 USD
      Aug 27Investing.comBIO

      This is the newest page. Registered accounts read further back.